Supreme Court stays 5th Circuit mifepristone in-person dispensing rule to 11 May 2026
Telehealth prescribers and mail-order pharmacy compliance teams handling mifepristone retain telemedicine and mail dispensing only until the administrative stay expires on 11 May 2026
Change
US Supreme Court Justice Samuel Alito issued an administrative stay on 4 May 2026 pausing for one week the 5th US Circuit Court of Appeals decision that would have reinstated an older federal rule requiring an in-person clinician visit to receive mifepristone, with Louisiana ordered to respond to the drugmakers' emergency requests by Thursday and the stay set to expire 11 May 2026.
Why it matters
The 5th Circuit's in-person visit requirement is unenforceable during the seven-day pause, leaving telemedicine prescribing and mail-order dispensing of mifepristone available only within the short validity window. The administrative stay is interim — it does not resolve the underlying legal challenge, and its expiry on 11 May 2026 returns the matter to active 5th Circuit jurisdiction unless extended or replaced by a Supreme Court ruling on the emergency requests filed by Danco Laboratories and GenBioPro.
Implications
- — Telehealth clinic operators and mail-order pharmacy compliance teams must scope mifepristone prescribing and dispensing without in-person visit to within the 11 May 2026 stay window — post-expiry operations become unlawful if the 5th Circuit rule reattaches.
- — Mifepristone manufacturers' legal teams (Danco Laboratories; GenBioPro) must prosecute emergency relief on the Supreme Court's briefing schedule — Louisiana's response deadline (Thursday) and stay expiry (11 May 2026) control whether current dispensing rules remain operative.
See full brief
Use 1 free preview to unlock implications, who’s affected, what to watch, and Clarify for this brief.
2 free previews left this month · Resets 1 Jun
Source